Flat dose regimen of toripalimab based on model-informed drug development approach

Introduction: Flat dosing regimen has recently been approved for programmed death receptor-1 (PD-1) inhibitors including toripalimab, nivolumab and pembrolizumab. The objective of this study is to provide pharmacological evidence for a flat dosing regimen of toripalimab by assessing the efficacy and...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Lili, Qu, Jianye, Song, Ming, Zhao, Qun, Yang, Yonghua, Tan, Xi, Hu, Yanyan, Li, Jing, Lin, Yunfei, Feng, Hui, Yao, Sheng, Keegan, Patricia, Chen, Meixia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9880172/
https://www.ncbi.nlm.nih.gov/pubmed/36712659
http://dx.doi.org/10.3389/fphar.2022.1069818

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9880172/
https://www.ncbi.nlm.nih.gov/pubmed/36712659
http://dx.doi.org/10.3389/fphar.2022.1069818

Ejemplares similares